sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group, Inc. Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a Form 8.3 regarding its interests in Avadel Pharmaceuticals plc. The disclosure, dated 11 December 2025, outlines Vanguard's position under the Irish Takeover Panel Act. This form is a regulatory requirement for entities holding significant interests in a company subject to a takeover.
The report reveals Vanguard's ownership of 5,593,994 ordinary shares, representing 5.74% of Avadel Pharmaceuticals. Additionally, Vanguard disclosed recent transactions involving Avadel's securities. It purchased 7,816 shares and sold 2,928 shares, both at USD 21.48 per share.
No cash-settled or stock-settled derivatives, nor any other complex transactions, were reported at this time. Furthermore, there are no current agreements or understandings related to voting rights, options, or derivatives tied to Avadel Pharmaceuticals.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.